<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690222</url>
  </required_header>
  <id_info>
    <org_study_id>CHDA-RS/2008-024</org_study_id>
    <nct_id>NCT00690222</nct_id>
  </id_info>
  <brief_title>Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery</brief_title>
  <official_title>A Comparison of Intracameral Phenylephrine 2% and Tropicamide 0.2% With Topical Phenylephrine 2.5% and Tropicamide 1% for Pupillary Dilation During Cataract Surgery on Patients With and Without Pseudoexfoliation Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to determine if an intracameral solution of 0.2% tropicamide and 2%
      phenylephrine can dilate the pupil for cataract surgery as well as pre-operative topical 1%
      tropicamide and 5% phenylephrine. We will be looking at two separate groups of patients,
      those with and those without pseudoexfoliation syndrome.

      We will be looking at how each method affects the size of the pupil at the beginning and at
      the end of cataract surgery. In addittion, we will look at what effect the two different
      methods have on blood pressure and heart rate in the pre-operative, peri-operative and
      post-operative periods.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pupil size</measure>
    <time_frame>At beginning and completion of cataract surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Peri-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Peri-operatively</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cataract</condition>
  <condition>Phacoemulsification</condition>
  <condition>Mydriasis</condition>
  <condition>Pseudoexfoliation Syndrome</condition>
  <arm_group>
    <arm_group_label>TM</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Topical mydriasis without pseudoexfoliation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracameral mydriasis without pseudoexfoliation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TM - PXF</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Topical mydriasis with pseudoexfoliation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICM - PXF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracameral Mydriasis with pseudoexfoliation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intracameral injection of mydriatic agent</intervention_name>
    <description>A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery</description>
    <arm_group_label>ICM</arm_group_label>
    <arm_group_label>ICM - PXF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to give consent

          -  Greater than 18 years of age

          -  Planned clear cornea cataract extraction and placement of foldable posterior chamber
             intraocular lens

          -  No secondary procedure planned (i.e. trabeculectomy, keratectomy, corneal transplant,
             vitreo-retinal procedure etc.)

          -  Systemic condition capable of undergoing topical anesthesia

          -  No previous intraocular surgery

          -  Pseudoexfoliation syndrome (PXF) for group 1

          -  No Pseudoexfoliation syndrome for group 2

        Exclusion Criteria:

          -  Not fulfilling inclusion criteria

          -  Any iris pathology including but not limited to posterior synechia, iridocorneal
             endothelial syndrome, corectopia, traumatic mydriasis, Horner's syndrome, Adie's
             pupil, cyclodialysis, iridodialysis

          -  Previous or concurrent use of FlomaxÂ® or similar alpha-antagonist medication

          -  Corneal pathology affecting pupil magnification or measurement (keratoconus,
             peripheral thinning, sclerocornea, scarring)

          -  Uncontrolled Hypertension (greater than 170/90 on pre-operative assessment on day of
             surgery as measured by automated DATEX monitor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cataract surgery</keyword>
  <keyword>phacoemulsification</keyword>
  <keyword>pupil</keyword>
  <keyword>dilation</keyword>
  <keyword>mydriasis</keyword>
  <keyword>intracameral</keyword>
  <keyword>topical</keyword>
  <keyword>pseudoexfoliation syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
    <mesh_term>Mydriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Tropicamide</mesh_term>
    <mesh_term>Mydriatics</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

